Market Cap (In USD)
20.33 Million
Revenue (In USD)
-
Net Income (In USD)
-12.47 Million
Avg. Volume
40.39 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.04-6.7499
- PE
- -
- EPS
- -
- Beta Value
- -0.28
- ISIN
- US64132R4048
- CUSIP
- 64132R107
- CIK
- 1638287
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Hyung-Heon Kim
- Employee Count
- -
- Website
- https://www.neurobopharma.com
- Ipo Date
- 2016-08-05
- Details
- NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
More Stocks
-
HPIL
-
300130XGD Inc.
300130
-
AKEArkema S.A.
AKE
-
BCOW
-
STA-R
-
TUSK
-
300852
-
CAMB3Cambuci S.A.
CAMB3